Effectiveness of Rivastigmine and Donepezil on cognitive disorders

Evaluation of the effectiveness of Rivastigmine and Donepezil on cognitive disorders in patients with moderate stroke

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20210819052232N1

Enrollment

165

Registered

2021-11-07

Start date

2021-11-22

Completion date

Unknown

Last updated

2021-11-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cognitive disorder. Mild cognitive impairment, so stated

Interventions

Intervention 1: Intervention group: Rivastigmine is prescribed for one month at a dose of 1.5 mg and then the dose will be increased by 3.5 mg. This drug is prescribed for patients in this group for u

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patient consent to enter the study Patients with moderate concussion with an GCS of 12-8.

Exclusion criteria

Exclusion criteria: Consciousness coefficient greater than 12 History of any brain disorders in the patient Patients with Acetylcholinesterase contraindications

Design outcomes

Primary

Measure	Time frame
Reduce cognitive impairment. Timepoint: After discharge and three months after. Method of measurement: MMSE, NUCog, Moca questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMehdi Shafiei

Esfahan University of Medical Sciences

Mehdishafiei82@gmail.com+98 31 3668 0048

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026